Pharmacokinetic/pharmacodynamic investigation for BPSD in dementia patients receiving donepezil.
| Project/Area Number |
25460215
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | University of Shizuoka |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Yoshiaki 国立病院機構, 静岡てんかん神経医療センター, 治験管理室主任 (60596245)
|
|---|
| Research Collaborator |
SAKAKIBARA Ayami
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | donepezil / BPSD / dementia / 認知症 / アルツハイマー病 / ドネペジル |
|---|
| Outline of Final Research Achievements |
Behavioral and psychological symptoms of dementia (BPSD) are big problem for the treatment of dementia. We investigated relationship between plasma concentration of donepezil, the most popular drug for dementia and the development of BPSD. First we developed the highly sensitive LC-MS/MS method for donepezil and its active metabolite, 6-O-desmethyldonepezil. Using this method we achieved the quantitation limits of both two drugs under 0.1 ng/mL. In the clinical study, although plasma concentration of 6-O-desmethyldonepezil did not correlated with development of BPSD, patients whose plasma concentration of donepezil were above 75 ng/mL did not developed BPSD. These results indicated that plasma concentration of donepezil influences the development of BPSD.
|
Report
(4 results)
Research Products
(8 results)
